Literature DB >> 9371821

Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice.

R Yamanaka1, C Barlow, J Lekstrom-Himes, L H Castilla, P P Liu, M Eckhaus, T Decker, A Wynshaw-Boris, K G Xanthopoulos.   

Abstract

Polymorphonuclear leukocytes are essential for host defense to infectious diseases. CCAAT/enhancer binding protein epsilon (C/EBP epsilon) is preferentially expressed in granulocytes and lymphoid cells. Mice with a null mutation in C/EBP epsilon develop normally and are fertile but fail to generate functional neutrophils and eosinophils. Opportunistic infections and tissue destruction lead to death by 3-5 months of age. Furthermore, end-stage mice develop myelodysplasia, characterized by proliferation of atypical granulocytes that efface the bone marrow and result in severe tissue destruction. Thus, C/EBP epsilon is essential for terminal differentiation and functional maturation of committed granulocyte progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371821      PMCID: PMC24284          DOI: 10.1073/pnas.94.24.13187

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Simplified mammalian DNA isolation procedure.

Authors:  P W Laird; A Zijderveld; K Linders; M A Rudnicki; R Jaenisch; A Berns
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

2.  A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus.

Authors:  P Antonson; B Stellan; R Yamanaka; K G Xanthopoulos
Journal:  Genomics       Date:  1996-07-01       Impact factor: 5.736

3.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

4.  A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells.

Authors:  L M Scott; C I Civin; P Rorth; A D Friedman
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

5.  BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

Authors:  J W Voncken; V Kaartinen; P K Pattengale; W T Germeraad; J Groffen; N Heisterkamp
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

6.  Fibroblast growth factor receptor 3 is a negative regulator of bone growth.

Authors:  C Deng; A Wynshaw-Boris; F Zhou; A Kuo; P Leder
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

Review 7.  Cytokine receptor signalling.

Authors:  J N Ihle
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

9.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  The NF-M transcription factor is related to C/EBP beta and plays a role in signal transduction, differentiation and leukemogenesis of avian myelomonocytic cells.

Authors:  S Katz; E Kowenz-Leutz; C Müller; K Meese; S A Ness; A Leutz
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

View more
  111 in total

Review 1.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

2.  Target acquisition and acute promyelocytic leukemia.

Authors:  D A Egan; R M Evans
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

3.  C/EBP epsilon mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut).

Authors:  A Khanna-Gupta; T Zibello; H Sun; J Lekstrom-Himes; N Berliner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 4.  Transcriptional regulation of myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

5.  The role of transcription factors in the guidance of granulopoiesis.

Authors:  Katja Fiedler; Cornelia Brunner
Journal:  Am J Blood Res       Date:  2012-01-01

6.  Neonatal sepsis and neutrophil insufficiencies.

Authors:  John Nicholas Melvan; Gregory J Bagby; David A Welsh; Steve Nelson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2010-06       Impact factor: 5.311

7.  T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage.

Authors:  Laleh Talebian; Zhe Li; Yalin Guo; Justin Gaudet; Maren E Speck; Daisuke Sugiyama; Prabhjot Kaur; Warren S Pear; Ivan Maillard; Nancy A Speck
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

Review 8.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

9.  Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway.

Authors:  Alexey M Chumakov; Agnes Silla; Elizabeth A Williamson; H Phillip Koeffler
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

Review 10.  Genetic susceptibility in childhood acute lymphoblastic leukemia.

Authors:  Angela Gutierrez-Camino; Idoia Martin-Guerrero; Africa García-Orad
Journal:  Med Oncol       Date:  2017-09-13       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.